北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品包括关节假体产品、脊柱类植入产品、创伤类产品、运动医学类产品、富血小 板血浆（PRP）产品、口腔类产品、手术机器人产品。关节假体产品涵盖髋、膝、肩、肘四大人体关 节。该公司产品销往国内外市场。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月27日南向资金增持16.82万股春立医疗（01858.HK）。近5个交易日中，获南向资金 增持的有3天，累计净增持15.2万股。近20个交易日中，获南向资金减持的有12天，累计净减持112.97万 股。截至目前，南向资金持有春立医疗（01858.HK）4121.68万股，占公司已发行普通股的43.31%。 ...

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 61,000 shares on February 13, 2023, despite a net reduction of 338,800 shares over the past five trading days [1] Group 1: Southbound Fund Activity - In the last five trading days, there were three days of net reductions in holdings by southbound funds, totaling 338,800 shares [1] - Over the past 20 trading days, there were ten days of net reductions, amounting to 246,800 shares [1] - As of now, southbound funds hold 41,125,800 shares of Chuangli Medical, representing 43.21% of the company's issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. primarily engages in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品包括关节假体产品、脊柱类植入产品、创伤类产品、运动医学类产品、富血小 板血浆（PRP）产品、口腔类产品、手术机器人产品。关节假体产品涵盖髋、膝、肩、肘四大人体关 节。该公司产品销往国内外市场。 证券之星消息，2月10日南向资金减持3.1万股春立医疗（01858.HK）。近5个交易日中，获南向资金减 持的有4天，累计净减持78.95万股。近20个交易日中，获南向资金减持的有11天，累计净减持90.12万 股。截至目前，南向资金持有春立医疗（01858.HK）4144.63万股，占公司已发行普通股的43.55%。 ...

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 12,700 shares on February 9, indicating a fluctuating interest from these investors in the company [1] Group 1: Southbound Fund Activity - Over the past five trading days, there were three days of net reductions in holdings by southbound funds, totaling a net decrease of 674,000 shares [1] - In the last twenty trading days, there were ten days of net reductions, with a cumulative net decrease of 769,000 shares [1] - Currently, southbound funds hold 41,477,300 shares of Chuangli Medical, accounting for 43.59% of the company's total issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. specializes in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Spring Medical (01858.HK) by 153,800 shares on February 5, 2026, marking a decrease of 0.37% [1][2] - Over the past five trading days, there have been three days of net reductions by southbound funds, totaling 427,300 shares [1] - In the last twenty trading days, there were eleven days of net reductions, amounting to 2,033,000 shares [1] Group 2 - As of now, southbound funds hold 41,678,300 shares of Spring Medical, which represents 43.79% of the company's total issued ordinary shares [1] - Spring Medical is primarily engaged in the research, development, production, and sales of implantable orthopedic medical devices, including joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [2] - The company's joint prosthetic products cover major human joints such as the hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [2]

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Spring Medical (01858.HK), indicating a net reduction in holdings over the past trading days [1] - On February 2, 2026, southbound funds increased their holdings by 74,000 shares, marking a 0.18% increase [2] - Over the last five trading days, there were four days of net reductions, totaling a decrease of 405,800 shares [1][2] - In the last 20 trading days, there were 11 days of net reductions, with a cumulative decrease of 3,113,500 shares [1] Group 2 - As of February 2, 2026, southbound funds hold a total of 42,151,300 shares of Spring Medical, which represents 44.29% of the company's issued ordinary shares [1] - Spring Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics, spinal implants, trauma products, sports medicine products, PRP products, oral products, and surgical robots [2] - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, and are sold in both domestic and international markets [2]

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook for participation in the upcoming stock issuance [22]. Core Insights - The company is a high-quality orthopedic consumables provider, established in 2015, with a focus on spinal, trauma, and sports medicine products. It ranks third in the domestic market for spinal vertebroplasty systems and sixth for spinal implant devices as of 2023 [3][7]. - The company has a competitive advantage in core technologies, with a total of 108 patents, including 41 invention patents, and has established a nationwide sales network [3][7]. - Revenue for 2024 is projected at 275 million yuan, with a slight decline over the past three years at a CAGR of -1.9%. However, non-collection products are expected to grow rapidly, potentially becoming a new growth driver [8][22]. - The company plans to use the raised funds primarily for expanding production capacity in orthopedic consumables, as well as for building a research and development center and marketing network [9][22]. Summary by Sections 1. Company Overview - The company specializes in orthopedic consumables and aims to provide comprehensive solutions for orthopedic surgeries. It has a diverse product matrix and a strong focus on R&D and customer service [3][7]. 2. Issuance Plan - The new stock issuance will adopt a direct pricing method, with an issue price of 7.67 yuan per share. The initial issuance scale is 29.53 million shares, accounting for 25% of the total post-issue share capital, with an expected market capitalization of 906 million yuan [12][13]. 3. Industry Situation - The aging population is driving an increase in the incidence of orthopedic diseases. The proportion of the population aged 65 and above reached 15.64% in 2022, up 5.17% from 2015. This demographic shift is expected to increase the demand for orthopedic products [16][14]. 4. Competitive Advantages - The company has developed a comprehensive product matrix that covers various orthopedic clinical indications. It has established a robust sales network across all provinces in China, enhancing its market presence and customer relationships [17][3]. 5. Comparable Companies - The company’s financial metrics, including a projected gross margin of 58.05% for 2024, are competitive compared to peers in the industry. The average PE ratio of comparable companies is 60, while the company’s PE ratio is significantly lower at 11.65 [21][23]. 6. Subscription Analysis - The company is positioned as a leading player in the medical dressing market, with strong competitive advantages in various segments. The current production capacity is highly utilized, and the planned expansion is expected to unlock growth potential [22].

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Chunli Medical (01858.HK) by 385,200 shares on January 29, with a total net reduction of 241,000 shares over the last five trading days and 3,009,300 shares over the last twenty trading days [1] - As of now, southbound funds hold 42,105,600 shares of Chunli Medical, accounting for 44.25% of the company's total issued ordinary shares [1] - Chunli Medical is primarily engaged in the research, development, production, and sales of implantable orthopedic medical devices, with key products including joint prosthetics, spinal implants, trauma products, sports medicine products, PRP products, oral products, and surgical robots [1] Group 2 - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [1]

Core Insights - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 21,200 shares on January 23 [1] - Over the past five trading days, there have been five days of net increases in holdings, totaling 995,300 shares [1] - In the last twenty trading days, there were eight days of net reductions, amounting to 2,141,500 shares [1] - Currently, southbound funds hold 42,367,800 shares of Chuangli Medical, representing 44.52% of the company's issued ordinary shares [1] Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. primarily engages in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow [1] - The company's products are sold in both domestic and international markets [1]

Group 1 - The core viewpoint of the article highlights the recent increase in southbound capital holdings in Chunli Medical (01858.HK), with a net increase of 113,800 shares on January 22 [1] - Over the past five trading days, Chunli Medical has seen an increase in southbound capital for four days, totaling a net increase of 865,300 shares [1] - In the last twenty trading days, there were eight days of net reduction in southbound capital, amounting to a total decrease of 1,949,000 shares [1] Group 2 - As of now, southbound capital holds 42,346,600 shares of Chunli Medical, representing 44.5% of the company's total issued ordinary shares [1] - Chunli Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with key products including joint prosthetics, spinal implants, trauma products, sports medicine products, PRP products, oral products, and surgical robots [1] - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [1]